RxDoctor Payments DataLook up a doctor →

Paul Boerema, MD

Adult Medicine · Cleveland, TNNPI 1396979233

Payments from drug & device makers

$11,055in general payments, 2019–2025

Across 670 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Pfizer$673
  • Bayer$438
  • plus $4K from 44 others

What the payments were for

  • Speaking & faculty fees$2002%
  • Food & beverage$10,81498%
  • Education$410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,055 in reported general payments places this provider in the 95th percentile of 22 adult medicine providers in Tennessee.

See all adult medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$187,879
Medicare patients
333
Services billed
5,800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$93,165
EliquisApixaban60$58,128
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$40,839
MounjaroTirzepatide38$40,782
XareltoRivaroxaban25$33,768
JanuviaSitagliptin Phosphate36$30,191
JardianceEmpagliflozin22$27,389
Soliqua 100-33Insulin Glargine/Lixisenatide23$26,089
Tresiba Flextouch U-200Insulin Degludec15$17,094
FarxigaDapagliflozin Propanediol26$15,861
LinzessLinaclotide12$11,104
PremarinEstrogens, Conjugated19$9,257
MyrbetriqMirabegron15$6,598
Atorvastatin Calcium419$3,087
Famotidine171$3,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,093$93,16568 claims
PfizerEliquis, Premarin, Paxlovid$673$68,815105 claims
GSKTrelegy Ellipta$101$40,83933 claims
Lilly USA, LLCMounjaro$1,007$40,78238 claims
Johnson & JohnsonXarelto$199$33,76825 claims
MerckJanuvia$83$30,19136 claims
Boehringer IngelheimJardiance$371$27,38922 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$246$26,08923 claims
AstraZenecaFarxiga$1,125$15,86126 claims
AbbVieLinzess, Armour Thyroid$1,224$12,80544 claims
Astellas Pharma US IncMyrbetriq$109$6,59815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 22 adult medicine providers in Tennessee.

Other adult medicine in Cleveland

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →